Zobrazeno 1 - 10
of 119
pro vyhledávání: '"Juliane S, Walz"'
Autor:
Susanne Jung, Annika Nelde, Yacine Maringer, Monika Denk, Lisa Zieschang, Christine Kammer, Melek Özbek, Peter Martus, Christopher Hackenbruch, Alexander Englisch, Jonas S. Heitmann, Helmut R. Salih, Juliane S. Walz
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
IntroductionAcute myeloid leukemia (AML) has a dismal prognosis, mostly due to minimal residual disease-driven relapse, making an elimination of persisting therapy-resistant leukemia progenitor/stem cells (LPCs) the main goal for novel therapies. Pep
Externí odkaz:
https://doaj.org/article/4ad85c4b3c4a4a858a9ec662b89e13e5
Autor:
Alexander Englisch, Clara Hayn, Susanne Jung, Jonas S. Heitmann, Christopher Hackenbruch, Yacine Maringer, Annika Nelde, Marcel Wacker, Monika Denk, Lisa Zieschang, Christine Kammer, Peter Martus, Helmut R. Salih, Juliane S. Walz
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
Chronic lymphocytic leukemia (CLL) is the most common form of leukemia among adults in Western countries. Despite the introduction of targeted therapies, including first-line Bruton’s tyrosine kinase inhibitor (BTKi) treatment, CLL remains largely
Externí odkaz:
https://doaj.org/article/dd7432dd452f4e3c895e7e3e1fbf5b55
Autor:
Claudia Tandler, Jonas S. Heitmann, Tanja M. Michel, Maddalena Marconato, Simon U. Jaeger, Christian M. Tegeler, Monika Denk, Marion Richter, Melek Tutku Oezbek, Yacine Maringer, Sarah M. Schroeder, Nicole Schneiderhan-Marra, Karl-Heinz Wiesmüller, Michael Bitzer, Natalia Ruetalo, Michael Schindler, Christoph Meisner, Imma Fischer, Hans-Georg Rammensee, Helmut R. Salih, Juliane S. Walz
Publikováno v:
International Journal of Infectious Diseases, Vol 139, Iss , Pp 69-77 (2024)
Objectives: T cell immunity is key for the control of viral infections including SARS-CoV-2, in particular with regard to immune memory and protection against arising genetic variants. Methods: We recently evaluated a peptide-based SARS-CoV-2 T cell
Externí odkaz:
https://doaj.org/article/c354f5fd26fd421f8230c3f45d62af98
Autor:
Tsima Abou Kors, Matthias Meier, Lena Mühlenbruch, Annika C. Betzler, Franziska Oliveri, Martin Bens, Jaya Thomas, Johann M. Kraus, Johannes Doescher, Adrian von Witzleben, Linda Hofmann, Jasmin Ezic, Diana Huber, Julian Benckendorff, Thomas F. E. Barth, Jens Greve, Patrick J. Schuler, Cornelia Brunner, Jonathan M. Blackburn, Thomas K. Hoffmann, Christian Ottensmeier, Hans A. Kestler, Hans-Georg Rammensee, Juliane S. Walz, Simon Laban
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
IntroductionThe human leukocyte antigen complex (HLA) is essential for inducing specific immune responses to cancer by presenting tumor-associated peptides (TAP) to T cells. Overexpressed tumor associated antigens, mainly cancer-testis antigens (CTA)
Externí odkaz:
https://doaj.org/article/395296b0c62b42a7af04bb14da175331
Autor:
Naomi Hoenisch Gravel, Annika Nelde, Jens Bauer, Lena Mühlenbruch, Sarah M. Schroeder, Marian C. Neidert, Jonas Scheid, Steffen Lemke, Marissa L. Dubbelaar, Marcel Wacker, Anna Dengler, Reinhild Klein, Paul-Stefan Mauz, Hubert Löwenheim, Mathias Hauri-Hohl, Roland Martin, Jörg Hennenlotter, Arnulf Stenzl, Jonas S. Heitmann, Helmut R. Salih, Hans-Georg Rammensee, Juliane S. Walz
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-12 (2023)
Abstract T cell recognition of human leukocyte antigen (HLA)-presented tumor-associated peptides is central for cancer immune surveillance. Mass spectrometry (MS)-based immunopeptidomics represents the only unbiased method for the direct identificati
Externí odkaz:
https://doaj.org/article/dbea2b72e80845b88f66d5852cf7b946
Publikováno v:
Wellcome Open Research, Vol 9 (2024)
Background Major histocompatibility class I (MHC-I, human leukocyte antigen [HLA]-I in humans) molecules present small fragments of the proteome on the cell surface for immunosurveillance, which is pivotal to control infected and malignant cells. Imm
Externí odkaz:
https://doaj.org/article/ab62c45160514459b941413a277bb80b
Autor:
Christopher Hackenbruch, Jens Bauer, Jonas S. Heitmann, Yacine Maringer, Annika Nelde, Monika Denk, Lisa Zieschang, Christine Kammer, Birgit Federmann, Susanne Jung, Peter Martus, Nisar P. Malek, Konstantin Nikolaou, Helmut R. Salih, Michael Bitzer, Juliane S. Walz
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
The DNAJB1-PRKACA fusion transcript was identified as the oncogenic driver of tumor pathogenesis in fibrolamellar hepatocellular carcinoma (FL-HCC), also known as fibrolamellar carcinoma (FLC), as well as in other tumor entities, thus representing a
Externí odkaz:
https://doaj.org/article/a2dd1647213e47a0b299877dea3ea6f4
Autor:
Susanne Jung, Richard F. Schlenk, Christopher Hackenbruch, Sandra S.L. Roldan Pinzon, Michael Bitzer, Martin Pflügler, Juliane S. Walz, Gundram Jung, Jonas S. Heitmann, Helmut R. Salih
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
IntroductionColorectal cancer (CRC) is the third most common cancer worldwide in men and women. In the metastasized stage, treatment options and prognosis are limited. To address the high medical need of this patient population, we generated a CD276x
Externí odkaz:
https://doaj.org/article/7f1c1453e6734dea9e21b4666171cfeb
Autor:
Ashish Goyal, Jens Bauer, Joschka Hey, Dimitris N. Papageorgiou, Ekaterina Stepanova, Michael Daskalakis, Jonas Scheid, Marissa Dubbelaar, Boris Klimovich, Dominic Schwarz, Melanie Märklin, Malte Roerden, Yu-Yu Lin, Tobias Ma, Oliver Mücke, Hans-Georg Rammensee, Michael Lübbert, Fabricio Loayza-Puch, Jeroen Krijgsveld, Juliane S. Walz, Christoph Plass
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-19 (2023)
Abstract Immunotherapies targeting cancer-specific neoantigens have revolutionized the treatment of cancer patients. Recent evidence suggests that epigenetic therapies synergize with immunotherapies, mediated by the de-repression of endogenous retrov
Externí odkaz:
https://doaj.org/article/78cbaff3798a429b8d0dd2100c9a8172
Autor:
Jonas S. Heitmann, Claudia Tandler, Maddalena Marconato, Annika Nelde, Timorshah Habibzada, Susanne M. Rittig, Christian M. Tegeler, Yacine Maringer, Simon U. Jaeger, Monika Denk, Marion Richter, Melek T. Oezbek, Karl-Heinz Wiesmüller, Jens Bauer, Jonas Rieth, Marcel Wacker, Sarah M. Schroeder, Naomi Hoenisch Gravel, Jonas Scheid, Melanie Märklin, Annika Henrich, Boris Klimovich, Kim L. Clar, Martina Lutz, Samuel Holzmayer, Sebastian Hörber, Andreas Peter, Christoph Meisner, Imma Fischer, Markus W. Löffler, Caroline Anna Peuker, Stefan Habringer, Thorsten O. Goetze, Elke Jäger, Hans-Georg Rammensee, Helmut R. Salih, Juliane S. Walz
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-10 (2023)
Abstract T-cell immunity is central for control of COVID-19, particularly in patients incapable of mounting antibody responses. CoVac-1 is a peptide-based T-cell activator composed of SARS-CoV-2 epitopes with documented favorable safety profile and e
Externí odkaz:
https://doaj.org/article/b32dbe5fcabf453983d2e107f672acc4